The Latvian Medicines Verification Organization (LZVO) informs that on October 14, the new Latvian Medicines Verification System (LZVS) release - version 7.0 - was successfully deployed in the production environment. The system is operating stably, and no technical issues have been identified.
As previously reported, the new LZVS release mainly includes technical updates that do not affect end users of the LZVS. The infrastructure improvements - including security enhancements - are intended to ensure continued system stability and optimal performance for system users. The end-user interface version v5 remains available for user connections.
The updated version 7.0 includes the following infrastructure improvements:
- enhanced security measures to ensure continued system stability and performance for users,
- improved user experience in the WebGUI portal by refining the password reset functionality,
- correction of previously identified minor issues.
In the reporting module, the main change affects the National Competent Authorities (NCA) I.1 Investigation Report. The new version allows the inclusion of additional information about L1–L4 level errors, excluding purely technical system activities, to provide a clearer overview of the history of actions taken on suspicious packs. Furthermore, NCAs will now be able to choose whether to generate the I.1 report using national-level data only or data from across Europe.
LZVO extends its gratitude to all parties involved for their contribution to ensuring that LZVS continues to maintain the highest level of security and offers system users increasingly efficient and user-friendly IT solutions.